Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's Cozaar Loses Patent Protection In Europe And Generics Quickly Arrive

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic competition starts in Europe for Merck blockbuster Cozaar heart drug.

You may also be interested in...

Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration

Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.

Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO

The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions

Merck/Schering: The Next Wave Of Consolidation

News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts